表紙
市場調査レポート

胃癌の検査・治療・予防:技術および世界市場

Gastric Cancer Testing, Treatment and Prevention: Technologies and Global Markets

発行 BCC Research 商品コード 342309
出版日 ページ情報 英文 183 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
胃癌の検査・治療・予防:技術および世界市場 Gastric Cancer Testing, Treatment and Prevention: Technologies and Global Markets
出版日: 2015年10月22日 ページ情報: 英文 183 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の胃癌診断/スクリーニングおよび治療市場規模、2014年に2,355億米ドルとなりました。同市場は2015年の2,417億米ドルから、2020年までに約3,183億米ドルへ、5.7%のCAGRで拡大すると予測されています。

当レポートでは、世界における胃癌の検査・治療・予防市場について取り上げ、市場の概要、市場動向の分析、臨床症状・診断・初期の胃癌に関連した詳細情報、現在・将来の治療・診断技術動向、開発フェーズ別によるパイプライン評価、ライセンシング合意に関する情報、および主要企業のプロファイルなどを提供しています。

第1章 イントロダクション

第2章 サマリー

第3章 癌

  • 癌とは?
  • 癌増殖の原因
  • 癌治療の戦略
  • 胃癌

第4章 胃癌のイントロダクション

  • 消化器官と癌
  • 胃癌の世界的な発生率
  • 胃癌の概要
  • 原因
  • 症状
  • 治療選択肢
  • 関連した癌・概要
  • 腎臓癌の標的療法
  • 膵臓癌
  • サマリー

第5章 胃癌のスクリーニング、診断および市場

  • スクリーニング
  • スクリーニング方法
  • スクリーニング・メリット
  • スクリーニングモダリティ
  • 米国における胃癌スクリーニング
  • 世界の胃癌スクリーニング

第6章 胃癌のスクリーニング・診断市場

  • スクリーニング
  • 診断・予後

第7章 胃癌の治療選択肢

  • 現在の治療

第8章 市場ダイナミクス・概要

  • 標準的な治療
  • 世界の癌市場動向
  • 開発中の医薬品
  • サマリー

第9章 胃癌治療・予防市場の規模・成長率

  • 市場:製品タイプ別
  • 市場:地域別

第10章 パイプライン・特許・新たな開発動向

  • 近年の開発動向・認可
  • 開発中の新薬/企業

第11章 世界の癌統計

  • 癌の動向
  • 新興市場
  • サマリー

第12章 企業・世界的企業

  • 企業
  • 癌市場のダイナミクス
  • 主要企業・プロファイル
    • BIOGEN IDEC
    • BRISTOL MYERS SQUIBB
    • ELI LILLY AND COMPANY
    • GLAXOSMITHKLINE
    • GENENTECH, INC
    • IMMUNOGEN
    • MERCK & COMPANY
    • NOVARTIS
    • PFIZER
    • ROCHE/GENENTECH
    • ONCOLYTICS
    • PACIFIC EDGE DIAGNOSTICS NZ
    • ZOVA BIOTHERAPEUTICS INC.

第13章 開発におけるパートナー

  • 研究開発の提携合意および技術・診断の合意

第14章 参考文献

図表

目次
Product Code: HLC174A

The global gastric cancer diagnostic/screening and treatment market was $235.5 billion in 2014. This market is expected to grow from $241.7 billion in 2015 to nearly $318.3 billion by 2020, with a compound annual growth rate (CAGR) of 5.7%.

This report provides:

  • An overview of the global markets for gastric cancer testing, treatment and prevention.
  • Analyses of market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020.
  • Detailed information pertaining to the clinical manifestations, diagnosis, and staging of early gastric cancer.
  • Analysis of recent and projected technological trends for treatment and diagnosis.
  • Assessment of the market's pipeline broken down by phase of development.
  • Information on licensing agreements as well as research and development partnerships and agreements.
  • Comprehensive company profiles of major players in the field.

image1

REPORT SCOPE

SCOPE AND FORMAT

This report will give an overall update on gastric cancer. It will review global markets for biologic therapeutics for gastric cancer and will forecast trends for use of diagnostics, screening and cancer treatment through 2020. It will cover important therapies, biologics, diagnostics, market share, products on the market and market share by company and statistical information for types of cancers prevalent worldwide, with special emphasis on the U.S. market. Current issues and trends affecting the industry, costs and factors influencing demand will be discussed. The report covers diagnostics, therapeutics, biological products in development, biological products in clinical trials, and currently marketed and late-stage developments in biologic cancer products. In addition, this report includes:

Treatment trends and sales patterns across major cancer indications with market performance of major pharmaceutical companies.

Forecast sales of leading products across major indications to 2020.

ANALYST'S CREDENTIALS

Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has more than 20 years of preclinical, alliance management, discovery and technology development, and marketing experience. Her strong focus areas include oncology and cardiovascular diseases with expertise in molecular and cell biology and complex cell-based biological assays including drug discovery, in vitro and in vivo screening, in vivo model development and pharmacokinetics. She has experience working with early startups.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE AND FORMAT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • RELATED BCC RESEARCH REPORTS
  • ANALYST'S CREDENTIALS
  • BCC RESEARCH WEBSITE
  • DISCLAIME

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, 2014-2020 ($ MILLIONS)

CHAPTER 3 CANCER

  • WHAT IS CANCER?
  • CAUSES OF CANCER GROWTH
  • CANCER TREATMENT STRATEGIES
    • COMMON TREATMENTS AND PROBLEMS
    • Surgery
    • Chemotherapy
    • Radiation Treatment
    • Hormone Therapy
    • Targeted Therapy
  • GASTRIC CANCER

CHAPTER 4 INTRODUCTION TO GASTRIC CANCER

  • TABLE 1 MAIN CATEGORIES OF CANCER
  • DIGESTIVE SYSTEM AND CANCER
    • ESOPHAGEAL CANCER
  • GASTRIC CANCER GLOBAL INCIDENCE
    • SUBTYPES AND CHARACTERISTICS
    • SMALL INTESTINE CANCER
  • STOMACH CANCER/GASTRIC CANCER OVERVIEW
  • TABLE 2 TYPES OF STOMACH CANCER
  • TABLE 3 THE STAGES OF ADENOCARCINOMA STOMACH CANCER
  • TABLE 4 TESTS AND PROCEDURES USED TO DIAGNOSE STOMACH CANCER
  • CAUSES
  • TABLE 5 RISK FACTORS
  • TABLE 6 CAUSES OF GASTRIC CANCER
  • SYMPTOMS
  • TABLE 7 SYMPTOMS
  • THERAPEUTIC OPTIONS
  • RELATED CANCERS AND OVERVIEW
    • KIDNEY CANCER
  • TARGETED THERAPIES FOR KIDNEY CANCER
  • TABLE 8 DRUGS APPROVED FOR KIDNEY (RENAL CELL) CANCER
    • SORAFENIB (NEXAVAR)
    • SUNITINIB (SUTENT)
    • TEMSIROLIMUS (TORISEL)
    • EVEROLIMUS (AFINITOR)
    • BEVACIZUMAB (AVASTIN)
    • PAZOPANIB (VOTRIENT)
    • AXITINIB (INLYTA)
  • LIVER
  • PANCREATIC CANCER
  • SUMMARY

CHAPTER 5 GASTRIC CANCER SCREENING, DIAGNOSIS AND MARKET

  • SCREENING
  • SCREENING METHODS
  • TABLE 9 GASTRIC SCREENING METHODS
  • SCREENING AND BENEFITS
  • SCREENING MODALITIES
    • Barium-Meal Gastric Photofluorography
    • Gastric Endoscopy
    • Serum Pepsinogen
  • GASTRIC SCREENING IN UNITED STATES
  • GASTRIC CANCER SCREENING WORLDWIDE
    • Conclusions

CHAPTER 6 GASTRIC SCREENING AND DIAGNOSIS MARKET

  • TABLE 10 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE OF STOMACH CANCER WORLDWIDE, 2012 (THOUSANDS)
  • SCREENING
  • TABLE 11 GLOBAL GASTRIC CANCER DIAGNOSTIC AND SCREENING MARKET, THROUGH 2020 ($ MILLIONS)
  • DIAGNOSIS AND PROGNOSIS
    • TESTS
    • TABLE 12 TESTS AND PROCEDURES TO DETECT GASTRIC CANCER
    • IMAGING TESTS
      • Upper Gastrointestinal (GI) Series
      • Computed Tomography (CT or CAT) Scan
      • Magnetic Resonance Imaging (MRI) Scan
      • Positron Emission Tomography (PET) Scan
      • Chest X-Ray
      • Laparoscopy
      • Helicobacer Pylori
      • TABLE 13 TESTS USED TO DETECT H. PYLORI
      • Lab Tests
      • Costs
      • TABLE 14 GASTROINTESTINAL ENDOSCOPY EXAMINATIONS IN U.S., 2009 (MILLIONS)
    • SERUM PEPSINOGEN PREDICTS GASTRIC ADENOCARCINOMA

CHAPTER 7 GASTRIC CANCER TREATMENT OPTIONS

  • CURRENT PRACTICES
  • TABLE 15 TYPES OF STANDARD TREATMENT
    • CHEMOPREVENTION
    • ANTIOXIDANTS
    • ANTIBIOTICS
      • Non-Steroidal Anti-Inflammatory Drugs (Including Aspirin)
    • STAGING
      • Sentinel Lymph Node Mapping
      • Surgery
      • Chemotherapy
      • Radiation Therapy
      • Chemoradiation
    • TARGETED THERAPY
      • Drugs Approved for Stomach (Gastric) Cancer
      • TABLE 16 APPROVED DRUGS FOR GASTRIC CANCER
    • PROGNOSIS
    • PREVENTION
    • CHEMOTHERAPY DRUGS AND COMBINATIONS
    • TARGETED THERAPY OVERVIEW
      • Pembrolizumab
      • Ramucirumab
      • Afinitor (Everolimus)
      • Apatinib
    • FAILED DRUGS
      • Cetuximab
      • Tykerb (Lapatinib)
      • Expected Treatment Outcomes
    • GASTROINTESTINAL CANCER: MONOCLONAL ANTIBODIES
    • TABLE 17 RECENT SURFACE ANTIGENS TARGETED BY MARKETED ANTIBODY THERAPEUTICS
    • TABLE 18 MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER TREATMENT
    • TABLE 19 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ MILLIONS)
    • FIGURE 1 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ MILLIONS)
    • TABLE 20 GASTRIC CANCER AND ANTIBODIES IN DEVELOPMENT
    • AVASTIN (BEVACIZUMAB)
    • HERCEPTIN (TRASTUZUMAB)
    • VECTIBIX (PANITUMUMAB)

CHAPTER 8 MARKET DYNAMICS AND OVERVIEW

  • TABLE 21 CANCER KEY FACTS
  • STANDARD TREATMENTS
  • GLOBAL CANCER MARKET TRENDS
  • TABLE 22 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLIONS OF PATIENTS)
  • FIGURE 2 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLION PATIENTS)
  • TABLE 23 GLOBAL CANCER RELATED ESTIMATED DEATHS BY REGION, 2012 AND 2030 (MILLIONS)
  • FIGURE 3 GLOBAL CANCER RELATED ESTIMATED DEATHS, BY REGION 2012 AND 2030 (MILLIONS)
  • TABLE 24 APPROVED ONCOLOGY DRUGS, 2013-2015
    • GLOBAL ONCOLOGY MARKET
    • TABLE 25 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 4 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, 2014-2020 ($ MILLIONS)
    • CANCER DRUGS: PAST PERFORMANCE
    • TABLE 26 GLOBAL SALES FOR ONCOLOGY DRUGS BY COMPANIES, 2012 AND 2013 ($ MILLIONS/%)
    • EMERGING MARKETS
    • TABLE 27 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, THROUGH 2020 ($ MILLIONS)
    • FIGURE 5 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, 2014-2020 ($ MILLIONS)
    • GASTRIC CANCER TREATMENT COSTS
      • Drugs Approved for Stomach (Gastric) Cancer
      • TABLE 28 GLOBAL MARKET FOR GASTRIC CANCER, THROUGH 2020 ($ MILLIONS)
      • FIGURE 6 GLOBAL MARKET FOR GASTRIC CANCER, 2014-2020 ($ MILLIONS)
      • TABLE 29 APPROVED DRUGS FOR GASTRIC CANCER TREATMENT
      • TABLE 30 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2020 ($ MILLIONS)
      • FIGURE 7 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2014-2020 ($ MILLIONS)
      • TABLE 31 GLOBAL SALES FOR APPROVED BIOLOGICAL TREATMENT OF GASTRIC CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
      • FIGURE 8 GLOBAL SALES FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS)
      • TABLE 32 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF GASTRIC CANCER-MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
      • FIGURE 9 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS)
  • DRUGS IN DEVELOPMENT
    • MAJOR PLAYERS
      • Roche
      • TABLE 33 PATENT EXPIRIES
      • Merck/Bristol-Myers Squibb
    • ISSUES AND TRENDS AFFECTING MARKET
  • SUMMARY

CHAPTER 9 GASTRIC CANCER TREATMENT AND PREVENTION MARKET SIZE AND GROWTH

  • MARKET BY PRODUCT TYPE
    • CYRAMZA
      • Kadcyla (ado-trastuzumab emtansine)
      • Perjeta
      • Herceptin
    • ONCOLOGY MARKET AND GROWTH
      • Leading Drugs
      • TABLE 34 CANCER DRUGS SALES AND FORECAST, 2013-2016 ($ MILLIONS)
  • MARKET BY GEOGRAPHICAL SEGMENTS
  • TABLE 35 ONCOLOGY TREATMENT, 2013 (BILLIONS)
    • ONCOLOGY PIPELINE
      • U.S. Market
    • JAPAN (ASIA) MARKET
    • TABLE 36 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
    • FIGURE 10 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCERMONOCLONAL ANTIBODIES, 2014-2020 ($ MILLIONS)
    • TABLE 37 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
    • FIGURE 11 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
    • EUROPE MARKET
    • TABLE 38 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
    • FIGURE 12 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2014-2020 ($ MILLIONS)
    • TABLE 39 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
    • ASIA MARKET
    • AUSTRALIA MARKET
    • SOUTH KOREA MARKET
    • CHINA MARKET
      • Gastric Cancer Market in China
    • TAIWAN MARKET
    • SINGAPORE MARKET
    • INDIA MARKET
      • BIOMAb-EGFR
      • TABLE 40 ASIA-PACIFIC COMPANIES IN ONCOLOGY

CHAPTER 10 PIPELINE, PATENTS AND NEW DEVELOPMENTS

  • RECENT DEVELOPMENTS AND APPROVALS
  • TABLE 41 APPROVED GASTRIC CANCER DRUGS, 2013-2014
  • NEW DRUGS/COMPANIES IN DEVELOPMENT
    • CLINICAL TRIALS IN ONCOLOGY
    • TABLE 42 ONCOLOGY CLINICAL TRIALS, 2009
    • FIGURE 13 ONCOLOGY CLINICAL TRIALS, 2009
      • Two New Clinical Trials for Advanced Gastric Cancer
      • TABLE 43 ROCHE - CLINICAL TRIALS
      • AZD4547
      • Pacific Edge
      • Oncolytics

CHAPTER 11 GLOBAL CANCER STATISTICS

  • CANCER TRENDS
  • TABLE 44 GLOBAL CANCER ESTIMATES, 2012 (MILLIONS)
  • TABLE 45 CANCER - NEW GLOBAL CASES DIAGNOSED, 2012 (EXCLUDING NON-MELANOMA SKIN CANCER)
  • TABLE 46 COMMONLY DIAGNOSED CANCERS WORLDWIDE, 2012 (MILLIONS)
  • TABLE 47 AGE-STANDARDIZED RATE PER 100,000, 2012
    • TRENDS OVER TIME
    • FUTURE TRENDS 2020
    • TABLE 48 NUMBER OF NEW CANCER CASES BY SITE, 2020 (MILLIONS/%)
    • CANCER CURE AND COSTS
    • CAUSES OF RISE IN CANCER CASES
    • TABLE 49 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION
    • PROJECTIONS TO 2030
    • TABLE 50 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)
    • FIGURE 14 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)
    • CURRENT CANCER TRENDS AND ECONOMIC BURDEN
      • The Burden of Cancer
  • EMERGING MARKETS
  • TABLE 51 GLOBAL INCIDENCE OF CANCER BY TYPE, 2012 (MILLIONS)
  • TABLE 52 GLOBAL MORTALITY OF CANCER BY TYPE, 2012 (MILLIONS)
    • CANCER PREVALENCE AND MARKET
    • GASTRIC CANCER
    • TABLE 53 ESTIMATED GASTRIC CANCERS BY REGION, 2012 (THOUSANDS)
    • TABLE 54 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF GASTRIC CANCER
    • AFRICA
    • ASIA
      • Cancer Prevention and Screening in Asia
    • CHINA AND JAPAN
      • Gastric H. pylori infection
        • Japan
        • China
    • MALAYSIA
    • INDIA
    • EUROPE
    • THE AMERICAS
    • TABLE 55 AMERICAS: CANCER FACTS
    • NORTH AMERICA
    • TABLE 56 UNITED STATES: LEADING NEW CANCER CASES, 2014
    • TABLE 57 UNITED STATES - LEADING NEW CANCER CASES, 2014
      • Canada
      • New Cases of Cancer in 2013
      • TABLE 58 PERCENT DISTRIBUTION OF ESTIMATED NEW STOMACH CANCER CASES, BY GENDER, IN CANADA, 2013 (%)
  • SUMMARY

CHAPTER 12 COMPANIES AND GLOBAL PLAYERS

  • COMPANIES
  • TABLE 59 GLOBAL PRESCRIPTION SALES FOR BIOLOGIC DRUGS, 2014 ($ MILLIONS)
  • CANCER MARKET DYNAMICS
  • SELECTED COMPANIES AND PROFILES
    • BIOGEN IDEC
    • BRISTOL MYERS SQUIBB
    • ELI LILLY AND COMPANY
    • GLAXOSMITHKLINE
    • GENENTECH, INC
      • Hoffmann-LA Roche INC.
    • IMMUNOGEN
    • MERCK & COMPANY
    • NOVARTIS
    • PFIZER
    • ROCHE/GENENTECH
    • ONCOLYTICS
    • PACIFIC EDGE DIAGNOSTICS NZ
    • ZOVA BIOTHERAPEUTICS INC.

CHAPTER 13 PARTNERS IN DEVELOPMENT

  • RESEARCH AND DEVELOPMENT PARTNERSHIP AGREEMENTS AND TECHNOLOGY AND DIAGNOSTIC AGREEMENTS

CHAPTER 14 REFERENCES

LIST OF TABLES

  • SUMMARY TABLE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
  • TABLE 1 MAIN CATEGORIES OF CANCER
  • TABLE 2 TYPES OF STOMACH CANCER
  • TABLE 3 THE STAGES OF ADENOCARCINOMA STOMACH CANCER
  • TABLE 4 TESTS AND PROCEDURES USED TO DIAGNOSE STOMACH CANCER
  • TABLE 5 RISK FACTORS
  • TABLE 6 CAUSES OF GASTRIC CANCER
  • TABLE 7 SYMPTOMS
  • TABLE 8 DRUGS APPROVED FOR KIDNEY (RENAL CELL) CANCER
  • TABLE 9 GASTRIC SCREENING METHODS
  • TABLE 10 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE OF STOMACH CANCER WORLDWIDE, 2012 (THOUSANDS)
  • TABLE 11 GLOBAL GASTRIC CANCER DIAGNOSTIC AND SCREENING MARKET, THROUGH 2020 ($ MILLIONS)
  • TABLE 12 TESTS AND PROCEDURES TO DETECT GASTRIC CANCER
  • TABLE 13 TESTS USED TO DETECT H. PYLORI
  • TABLE 14 GASTROINTESTINAL ENDOSCOPY EXAMINATIONS IN U.S., 2009 (MILLIONS)
  • TABLE 15 TYPES OF STANDARD TREATMENT
  • TABLE 16 APPROVED DRUGS FOR GASTRIC CANCER
  • TABLE 17 RECENT SURFACE ANTIGENS TARGETED BY MARKETED ANTIBODY THERAPEUTICS
  • TABLE 18 MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER TREATMENT
  • TABLE 19 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ MILLIONS)
  • TABLE 20 GASTRIC CANCER AND ANTIBODIES IN DEVELOPMENT
  • TABLE 21 CANCER KEY FACTS
  • TABLE 22 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLIONS OF PATIENTS)
  • TABLE 23 GLOBAL CANCER RELATED ESTIMATED DEATHS BY REGION, 2012 AND 2030 (MILLIONS)
  • TABLE 24 APPROVED ONCOLOGY DRUGS, 2013-2015
  • TABLE 25 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 26 GLOBAL SALES FOR ONCOLOGY DRUGS BY COMPANIES, 2012 AND 2013 ($ MILLIONS/%)
  • TABLE 27 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, THROUGH 2020 ($ MILLIONS)
  • TABLE 28 GLOBAL MARKET FOR GASTRIC CANCER, THROUGH 2020 ($ MILLIONS)
  • TABLE 29 APPROVED DRUGS FOR GASTRIC CANCER TREATMENT
  • TABLE 30 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2020 ($ MILLIONS)
  • TABLE 31 GLOBAL SALES FOR APPROVED BIOLOGICAL TREATMENT OF GASTRIC CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
  • TABLE 32 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF GASTRIC CANCER-MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
  • TABLE 33 PATENT EXPIRIES
  • TABLE 34 CANCER DRUGS SALES AND FORECAST, 2013-2016 ($ MILLIONS)
  • TABLE 35 ONCOLOGY TREATMENT, 2013 (BILLIONS)
  • TABLE 36 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
  • TABLE 37 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
  • TABLE 38 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
  • TABLE 39 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
  • TABLE 40 ASIA-PACIFIC COMPANIES IN ONCOLOGY
  • TABLE 41 APPROVED GASTRIC CANCER DRUGS, 2013-2014
  • TABLE 42 ONCOLOGY CLINICAL TRIALS, 2009
  • TABLE 43 ROCHE - CLINICAL TRIALS
  • TABLE 44 GLOBAL CANCER ESTIMATES, 2012 (MILLIONS)
  • TABLE 45 CANCER - NEW GLOBAL CASES DIAGNOSED, 2012 (EXCLUDING NON-MELANOMA SKIN CANCER)
  • TABLE 46 COMMONLY DIAGNOSED CANCERS WORLDWIDE, 2012 (MILLIONS)
  • TABLE 47 AGE-STANDARDIZED RATE PER 100,000, 2012
  • TABLE 48 NUMBER OF NEW CANCER CASES BY SITE, 2020 (MILLIONS/%)
  • TABLE 49 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION
  • TABLE 50 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)
  • TABLE 51 GLOBAL INCIDENCE OF CANCER BY TYPE, 2012 (MILLIONS)
  • TABLE 52 GLOBAL MORTALITY OF CANCER BY TYPE, 2012 (MILLIONS)
  • TABLE 53 ESTIMATED GASTRIC CANCERS BY REGION, 2012 (THOUSANDS)
  • TABLE 54 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF GASTRIC CANCER
  • TABLE 55 AMERICAS: CANCER FACTS
  • TABLE 56 UNITED STATES: LEADING NEW CANCER CASES, 2014
  • TABLE 57 UNITED STATES - LEADING NEW CANCER CASES, 2014
  • TABLE 58 PERCENT DISTRIBUTION OF ESTIMATED NEW STOMACH CANCER CASES, BY GENDER, IN CANADA, 2013 (%)
  • TABLE 59 GLOBAL PRESCRIPTION SALES FOR BIOLOGIC DRUGS, 2014 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, 2014-2020 ($ MILLIONS)
  • FIGURE 1 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ MILLIONS)
  • FIGURE 2 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLION PATIENTS)
  • FIGURE 3 GLOBAL CANCER RELATED ESTIMATED DEATHS, BY REGION 2012 AND 2030 (MILLIONS)
  • FIGURE 4 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, 2014-2020 ($ MILLIONS)
  • FIGURE 5 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, 2014-2020 ($ MILLIONS)
  • FIGURE 6 GLOBAL MARKET FOR GASTRIC CANCER, 2014-2020 ($ MILLIONS)
  • FIGURE 7 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2014-2020 ($ MILLIONS)
  • FIGURE 8 GLOBAL SALES FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS)
  • FIGURE 9 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS)
  • FIGURE 10 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER- MONOCLONAL ANTIBODIES, 2014-2020 ($ MILLIONS)
  • FIGURE 11 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
  • FIGURE 12 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2014-2020 ($ MILLIONS)
  • FIGURE 13 ONCOLOGY CLINICAL TRIALS, 2009
  • FIGURE 14 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)
Back to Top